FrancophonIA/ELRC3.0 huggingface dataset:
English: Table 2 Rydapt dose interruption, reduction and discontinuation recommendations in patients with ASM, SM-AHN or MCL
Slovenian: Preglednica 2 Priporočila za prekinitev, znižanje ali ukinitev odmerjanja zdravila Rydapt pri bolnikih z agresivno sistemsko mastocitozo, sistemsko mastocitozo s pridruženo hematološko neoplazmo ali mastocitno levkemijo
English: The CGP52421, Cmin,ss in the AML and the ASM, SM-AHN, MCL population were 8630 ng/ml and 2860 ng/ml, respectively.
Slovenian: Cmin, ss metabolita CGP52421 pri bolnikih z akutno mieloično levkemijo je bila 8.630 ng/ml, pri bolnikih z agresivno sistemsko mastocitozo, sistemsko mastocitozo s pridruženo hematološko neoplazmo ali mastocitno levkemijo pa 2.860 ng/ml.
English: Median DFS in months (95% CI) 26.7 (19.4, NE) 15.5 (11.3, 23.5) 0.71 (0.55, 0.92) 0.0051 Complete Remission (CR) within 60 days of treatment start
Slovenian: 26,7 (19,4, NO) 15,5 (11,3, 23,5) 0,71 (0,55, 0,92) 0,0051
English: Final CSR: September
Slovenian: september 2021 (končno poročilo o študiji)
English: PAES: In order to investigate the efficacy in elderly patients, the MAH should submit the final results of a phase II ADE02T study of midostaurin in combination with intensive induction, consolidation including allogenic SCT and single agent maintenance in patients aged 18-70 with FLT3 ITD mutated AML.
Slovenian: Študija učinkovitosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PAES): Imetnik dovoljenja za promet mora predložiti rezultate študije faze II z oznako ADE02T z midostavrinom v kombinaciji z intenzivnim indukcijskim zdravljenjem in v okviru konsolidacijskega zdravljenja vključno s presaditvijo homolognih matičnih celic ter vzdrževalnim zdravljenjem z enim samim zdravilom pri bolnikih, starih od 18 do 70 let, z akutno mieloično levkemijo s prisotno mutacijo FLT3-ITD, s katero so raziskovali učinkovitost zdravila pri starejših bolnikih.
English: 9/l) was generally reversible by withholding Rydapt until recovery and discontinuation in the ASM, SM-AHN and MCL studies.
Slovenian: 9/l) je večinoma izzvenela po prekinitvi odmerjanja zdravila Rydapt do normalizacije izvidov oziroma po ukinitvi zdravila v študijah agresivne sistemske mastocitoze, sistemske mastocitoze s pridruženo hematološko neoplazmo in mastocitne levkemije.
English: Grade 3/4 pulmonary infiltrates
Slovenian: Odmerjanje zdravila Rydapt indukcijska, konsolidacijska in vzdrževalna pljučni infiltrati 3. oziroma 4. stopnje
English: Some side effects in patients with ASM, SM-AHN and MCL could be serious.
Slovenian: Nekateri neželeni učinki pri bolnikih z agresivno sistemsko mastocitozo, sistemsko mastocitozo s pridruženo hematološko neoplazmo in mastocitno levkemijo so lahko resni.
English: Discontinue Rydapt if low ANC persists for >21 days and is suspected to be related to Rydapt.
Slovenian: V primeru vztrajno znižanega AŠN >21 dni in suma, da je znižanje povezano z zdravilom Rydapt, je treba zdravilo Rydapt povsem ukiniti.
English: STATEMENT OF ACTIVE SUBSTANCE(S)
Slovenian: zvišana vrednost aspartat aminotransferaze (AST)*
English: HR (95% CI)
Slovenian: (95 % IZ)
English: Stable disease, n (%) Progressive disease, n
Slovenian: delni odziv, n (%) stabilna bolezen, n (%) napredovanje bolezni, n (%) Sekundarni cilji opazovanja mediano trajanje odziva, meseci (95 % IZ)
English: 0.7 Uncommon
Slovenian: NO 0,073
English: Common (may affect up to 1 in every 10 people) - upper respiratory tract infection - nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle weakness and twitching (signs of high levels of calcium in the blood, known as hypercalcaemia) - fainting - involuntary shaking of the body - headache, dizziness (high blood pressure) - fast heart beat (sinus tachycardia) - collection of fluid around the heart, which, if severe, can decrease the heart's ability to pump blood (pericardial effusion) - fluid collection in the lungs/chest cavity, which, if severe, could make you breathless (pleural effusion) - sore throat and a runny nose - swelling of the eyelid - discomfort in the anus and rectum - abdominal pain, nausea, vomiting, constipation (abdominal discomfort) - dry skin - eye pain, blurred vision, intolerance to light (keratitis) - neck pain - bone pain - pain in limbs - increased weight - blood clotted in the catheter - abnormal blood test results which can indicate to your doctor how well certain parts of your body are functioning: high levels of uric acid
Slovenian: Pogosti (lahko se pojavijo pri največ 1 od 10 ljudi) - okužba zgornjih dihal - občutek slabosti, bruhanje, zaprtje, bolečine v trebuhu, pogosto uriniranje, žeja, šibkost in trzanje mišic (znaki visoke ravni kalcija v krvi, kar imenujemo tudi hiperkalciemija) - omedlevica - nehoteno tresenje telesa - glavobol, omotičnost (visok krvni tlak) - hitro bitje srca (sinusna tahikardija) - zastajanje tekočine okrog srca, ki lahko, če je obsežno, ovira srce pri črpanju krvi po telesu
English: The CGP62221 Cmin, ss in the AML and the ASM, SM-AHN, MCL population were 1610 ng/ml and 2020 ng/ml, respectively.
Slovenian: Cmin, ss metabolita CGP62221 pri bolnikih z akutno mieloično levkemijo je bila 1.610 ng/ml, pri bolnikih z agresivno sistemsko mastocitozo, sistemsko mastocitozo s pridruženo hematološko neoplazmo ali mastocitno levkemijo pa 2.020 ng/ml.
English: DFS (CR induction) (HR)
Slovenian: zvišana vrednost alanin aminotransferaze (ALT)*
English: Monitoring during treatment with Rydapt
Slovenian: Odmerjanje zdravila Rydapt
English: Table 4 Adverse drug reactions observed in the ASM, SM-AHN and MCL clinical studies
Slovenian: Preglednica 4 Neželeni učinki, ki so jih opažali v kliničnih študijah agresivne sistemske mastocitoze, sistemske mastocitoze s pridruženo hematološko neoplazmo in mastocitne levkemije
English: Nervous system disorders Headache
Slovenian: Bolezni živčevja glavobol sinkopa pogosti tremor pogosti
English: Median EFS in months, considering CRs within 60 days of treatment start (95% CI)
Slovenian: popolna remisija v 60 dneh od začetka zdravljenja
English: Package leaflet: Information for the patient
Slovenian: Shranjevanje zdravila Rydapt Vsebina pakiranja in dodatne informacije
English: sore throat or mouth ulcers (signs of a low level of blood cells) - fever, cough, difficult or painful breathing, wheezing, chest in pain when breathing (signs of pneumonia) - infections, fever, dizziness, light-headedness, decreased urination, rapid pulse, rapid breathing
Slovenian: Takoj obvestite zdravnika, farmacevta ali medicinsko sestro, če opazite katero od naslednjih težav: - šibkost, pojavljanje krvavitev ali modric brez očitnega vzroka, pogoste okužbe z znaki, kot so zvišana telesna temperatura, mrazenje, vneto grlo oziroma žrelo ali razjede v ustih (to so znaki znižanega števila krvnih celic), - huda zadihanost, oteženo in neobičajno hitro dihanje, omotičnost, občutek, da boste izgubili zavest, zmedenost in izjemna utrujenost (to so znaki sindroma akutne dihalne stiske), - okužbe, zvišana telesna temperatura, nizek krvni tlak, zmanjšano odvajanje vode, hiter srčni utrip, hitro dihanje (to so znaki sepse ali nevtropenične sepse).
English: Safety profile during maintenance phase
Slovenian: Faza zdravljenja Kriterij
English: Respiratory, thoracic and mediastinal disorders Epistaxis
Slovenian: Bolezni krvi in limfatičnega sistema febrilna nevtropenija petehije limfopenija
English: No impact of hepatic impairment could be identified in patients with mild or moderate hepatic impairment in the ASM, SM-AHN, MCL and AML populations.
Slovenian: Pri tem v populacijah bolnikov z agresivno sistemsko mastocitozo, sistemsko mastocitozo s pridruženo hematološko neoplazmo ali mastocitno levkemijo oziroma z akutno mieloično levkemijo niso ugotovili nobenega vpliva okvare jeter pri bolnikih z blago ali zmerno okvaro jeter.
English: PA/Al/PVC-Al blisters.
Slovenian: Pretisni omoti iz poliamida/aluminija/polivinilklorida (PA/Al/PVC-Al).
English: Oropharyngeal pain
Slovenian: PODATKI NA ZUNANJI OVOJNINI
English: 90 (3 x 30) tablets (multipack)
Slovenian: 90 (3 x 30) tablet, (pakiranje po več enot)
English: Germany considered that the granting of the marketing authorisation constitutes a potential serious risk to public health.
Slovenian: Nizozemska in Nemčija sta menili, da odobritev dovoljenja za promet z zdravilom predstavlja morebitno resno tveganje za javno zdravje;
English: Overall summary of the scientific evaluation of Methylphenidate Hexal and associated names (see Annex I)
Slovenian: Splošni povzetek znanstvenega vrednotenja zdravila Methylphenidate Hexal in povezanih imen (glejte Prilogo I)
English: The major concern raised by Germany could not be solved during the CMD(h) referral, and the issue was therefore referred to the CHMP.
Slovenian: Glavnega pomisleka, ki sta ga izpostavili Nemčija in Nizozemska, med napotitvenim postopkom skupine CMD(h) ni bilo mogoče odpraviti, zato je bila zadeva posredovana odboru CHMP.
English: The application for Methylphenidate Hexal is therefore based on bioequivalence studies between the applied and the reference product.
Slovenian: Uporaba zdravila Methylphenidate Hexal temelji na študijah biološke enakovrednosti med uporabljenim in referenčnim zdravilom.
English: • The Committee is of the opinion that bioequivalence was demonstrated under fasting conditions for the immediate and prolonged release phases and under fed conditions for the prolonged release phase.
Slovenian: • odbor meni, da je bila biološka enakovrednost pri pogojih na tešče dokazana za fazi s takojšnjim in podaljšanim sproščanjem ter pri pogojih na poln želodec za fazo s podaljšanim sproščanjem;
English: However, the Committee is of the opinion that the observed deviation is attributed to variability between subjects and to physiological conditions after intake of a high fat meal and this does not translate into differences in quality between Methylphenidate Hexal and the reference formulations.
Slovenian: Vendar odbor meni, da je opaženi odklon posledica variabilnosti med preskušanci in fiziološkega stanja po vnosu obroka z veliko vsebnostjo maščobe, kar ne pomeni razlik v kakovosti med zdravilom Methylphenidate Hexal in referenčnimi formulacijami;
English: Regarding the results obtained in the fed study (2009-18-PRT-2) it was shown that when compared to the fasting study several subjects did not have a biphasic profile but a continuous profile without an early maximum, whereby methylphenidate concentrations slowly increase after an erratic lag time.
Slovenian: Na podlagi rezultatov, pridobljenih v študiji pri pogojih na poln želodec (2009-18-PRT-2), so pokazali, da v primerjavi s študijo pri pogojih na tešče mnogi preskušanci niso imeli dvofaznega profila, ampak neprekinjen profil brez zgodnje največje koncentracije, pri čemer so se koncentracije metilfenidata povečevale z nerednim časovnim zamikom.
English: • The Committed reviewed all the data submitted by the applicant in order to support the bioequivalence between Methylphenidate Hexal 18 mg, 36 mg, 54 mg prolonged release tablets and the reference product.
Slovenian: • odbor je pregledal vse podatke, ki jih je predlagatelj predložil v podporo biološki enakovrednosti med zdravilom Methylphenidate Hexal 18 mg, 36 mg, 54 mg tablete s podaljšanim sproščanjem in referenčnim zdravilom;
English: Methylphenidate Hexal's formulation is designed with an outer coating containing the immediaterelease part surrounding the prolonged-release core (osmotic controlled).
Slovenian: Formulacija zdravila Methylphenidate Hexal je zasnovana z zunanjo oblogo, ki vsebuje del s takojšnjim sproščanjem, ta del pa obkroža jedro s podaljšanim sproščanjem (osmotsko nadzorovanim).
English: Methylphenidate Hexal which contains the active substance methylphenidate hydrochloride is an osmotic controlled prolonged release film coated tablet with a bi-layer core.
Slovenian: Zdravilo Methylphenidate Hexal, ki vsebuje zdravilno učinkovino metilfenidatijev klorid, je osmozno nadzorovana, filmsko obložena tableta s podaljšanim sproščanjem z dvoplastnim jedrom.
English: Waiver of studies under fed conditions for the 18 mg and 36 mg strengths The bioequivalence under fed conditions has only been studied in the 54 mg strength.
Slovenian: Opustitev študij pri pogojih na poln želodec za jakosti 18 mg in 36 mg Biološka enakovrednost pri pogojih na poln želodec je bila preučevana samo z jakostjo 54 mg.
English: The repeat-use MRP marketing authorisation application presented for the medicinal product Methylphenidate Hexal 18mg, 36mg, 54mg tablets is a generic application in accordance with the Article 10.1 of the Directive 2001/83/EC.
Slovenian: Vloga za pridobitev dovoljenja za promet z zdravilom Methylphenidate Hexal 18 mg, 36 mg, 54 mg tablete za večkratno uporabo s postopkom z medsebojnim priznavanjem je generična vloga v skladu s členom 10.1 Direktive 2001/83/ES.
English: The fed study failed to fulfil the standard acceptance criteria for bioequivalence for the immediaterelease phase (AUC(0-2h) and Cmax(0-2h)).
Slovenian: Študija pri pogojih na poln želodec ni izpolnila standardnih meril za sprejemljivost biološke enakovrednosti za fazo s takojšnjim sproščanjem (AUC (0-2h) in Cmax(0-2h)).
English: Methylphenidate Hexal (18 mg, 36 mg and 54 mg) is indicated in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in children aged between 6 and 18 years old once daily in the morning and can be taken with or without food.
Slovenian: Zdravilo Methylphenidate Hexal (18 mg, 36 mg in 54 mg) je indicirano za zdravljenje motnje pomanjkanja pozornosti s hiperaktivnostjo (ADHD) pri otrocih, starih od 6 do 18 let.
English: The repeat-use MRP was closed on day 210, with Germany which did not agree with the conclusions of the RMS's assessment report and which raised a potential serious risk to public health (PSRPH).
Slovenian: Postopek z medsebojnim priznavanjem za večkratno uporabo se je končal 210. dan, pri čemer se je večina zadevnih držav članic strinjala z zaključki poročila o oceni referenčne države članice, z izjemo Nemčije in Nizozemske, ki sta izpostavili morebitno resno tveganje za javno zdravje.
English: The results showed that bioequivalence was demonstrated for the studies under fasted conditions between Methylphenidate Hexal (18mg, 36mg, 54mg) and the reference product for the immediate and prolonged release phase.
Slovenian: Rezultati so pokazali, da je bila biološka enakovrednost med zdravilom Methylphenidate Hexal (18 mg, 36 mg, 54 mg) in referenčnim zdravilom dokazana pri študijah pri pogojih na tešče za fazi s takojšnjim ter podaljšanim sproščanjem.
English: the CHMP has recommended the granting of the marketing authorisations for which the summary of product characteristics, labelling and package leaflet remain as per the final versions achieved during the Coordination group procedure as mentioned in Annex III for Methylphenidate Hexal and associated names (see Annex I).
Slovenian: • odbor meni, da je opustitev študij manjših jakosti (18 mg in 36 mg) pri pogojih na poln želodec upravičena; je odbor CHMP priporočil odobritev dovoljenj za promet z zdravilom, pri katerih povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo ostajajo enaki kot v končnih različicah, pripravljenih med postopkom skupine za usklajevanje, kot je navedeno v Prilogi III za zdravilo Methylphenidate Hexal in povezana imena (glejte Prilogo I).
English: The marketing authorisation holder is Eisai Ltd.
Slovenian: Imetnik dovoljenja za promet je Eisai Ltd.
English: Further information on Panretin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Panretin so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: • other treatments (radiotherapy or chemotherapy) are not suitable, and
Slovenian: • druge oblike zdravljenja (radioterapija ali kemoterapija) niso primerne in
English: It may be used after this period but only on lesions that are responding to treatment.
Slovenian: Lahko se uporablja tudi po tem obdobju, vendar le pri lezijah, ki se odzivajo na zdravljenje.
English: Around 35% and 37% of the patients using Panretin responded to treatment compared with 18% and 7% of the patients using placebo.
Slovenian: Na zdravljenje se je odzvalo približno 35 in 37 % bolnikov, ki so uporabljali zdravilo Panretin, v primerjavi z 18 in 7 % bolnikov, ki so uporabljali placebo.
English: • the skin is not broken and the lesions are not swollen,
Slovenian: • koža ni počila in lezije niso otekle;
English: The main measure of effectiveness was the proportion of patients
Slovenian: Glavno merilo učinkovitosti je bil
English: • treatment for visceral (internal) Kaposi's sarcoma is not needed.
Slovenian: • zdravljenje visceralnega (internega) Kaposijevega sarkoma ni potrebno.
English: Panretin should be used for up to 12 weeks.
Slovenian: Zdravilo Panretin se uporablja do 12 tednov.
English: Panretin received a marketing authorisation valid throughout the EU on 11 October 2000.
Slovenian: Za zdravilo Panretin je bilo 11. oktobra 2000 izdano dovoljenje za promet, veljavno po vsej EU.
English: The European Medicines Agency decided that Panretin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Panretin večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
English: • the lesions have not responded to HIV treatment,
Slovenian: • se lezije niso odzvale na zdravljenje HIV;
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Panretin have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Panretin upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: It must not be used to treat lesions that are close to areas affected by other skin disorders.
Slovenian: Ne sme se uporabljati za zdravljenje lezij v bližini površin, ki so jih prizadele druge kožne bolezni.
English: Other information about Panretin
Slovenian: Druge informacije o zdravilu Panretin
English: who responded to treatment.
Slovenian: delež bolnikov, ki so se odzvali na zdravljenje.
English: What measures are being taken to ensure the safe use of Panretin?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Panretin?
English: Panretin is used when:
Slovenian: Zdravilo Panretin se uporablja, kadar:
English: Panretin is available as a gel to be applied to the skin lesions twice a day, using enough gel to cover each lesion with a generous coating and then leaving it to dry for three to five minutes before covering with clothing.
Slovenian: Zdravilo Panretin je na voljo kot gel, ki ga bolniki nanesejo na kožne lezije dvakrat dnevno, pri čemer je treba uporabiti dovolj gela, da prekrijejo vsako lezijo z obilnim nanosom, in počakati tri do pet minut, da se posuši, preden lezije prekrijejo z obleko.
English: The most common side effects with Panretin (which may affect more than 1 patient in 10) are rash, pruritus (itching), skin disorders (cracking, scabbing, crusting, draining, oozing) and pain (burning, soreness).
Slovenian: Najpogostejši neželeni učinki zdravila Panretin (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so izpuščaj, pruritus (srbenje), bolezni kože (pokanje kože, nastajanje krast, krastavost, izločanje tekočine, izcedki) in bolečina (pekoča bolečina, občutljivost).
English: As for all medicines, data on the use of Panretin are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Panretin stalno spremljajo.
English: Side effects reported with Panretin are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Panretin, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: What benefits of Panretin have been shown in studies?
Slovenian: Kakšne koristi zdravila Panretin so se pokazale v študijah?
English: Panretin must not be used in people who may be hypersensitive (allergic) to retinoids in general, alitretinoin, or any of the other ingredients.
Slovenian: Zdravila Panretin ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) retinoide na splošno, alitretinoin ali katero koli drugo sestavino zdravila.
English: An overview of Panretin and why it is authorised in the EU
Slovenian: Pregled zdravila Panretin in zakaj je odobreno v EU
English: Why is Panretin authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Panretin odobreno v EU?
English: Panretin must also not be used in women who are pregnant or who are planning a pregnancy, or who are breast-feeding.
Slovenian: Zdravila Panretin ne smejo uporabljati nosečnice in ženske, ki načrtujejo nosečnost, ter doječe matere.
English: For more information about using Panretin, see the package leaflet or contact a doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Panretin glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: The active substance in Panretin, alitretinoin, is an anticancer agent that belongs to the group ‘retinoids', substances that are derived from vitamin A. The exact way alitretinoin works in Kaposi's sarcoma is unknown.
Slovenian: Učinkovina v zdravilu Panretin, alitretinoin, je protirakava snov, ki spada v skupino „retinoidov“, snovi, pridobljenih iz vitamina A. Točen način delovanja alitretinoina pri Kaposijevem sarkomu ni znan.
English: Panretin was compared with placebo (a dummy treatment) in two 12-week studies involving a total of 402 patients with Kaposi's sarcoma.
Slovenian: Zdravilo Panretin so primerjali s placebom (zdravilom brez učinkovine) v dveh 12-tedenskih študijah, v katerih sta sodelovala skupno 402 bolnika s Kaposijevim sindromom.
English: What is Panretin and what is it used for?
Slovenian: Kaj je zdravilo Panretin in za kaj se uporablja?
English: What are the risks associated with Panretin?
Slovenian: Kakšna tveganja so povezana z zdravilom Panretin?
English: Panretin can only be obtained with a prescription and treatment should be started and maintained by a doctor with experience in treating Kaposi's sarcoma.
Slovenian: Predpisovanje in izdaja zdravila Panretin je le na recept, zdravljenje pa mora uvesti in vzdrževati zdravnik z izkušnjami z zdravljenjem Kaposijevega sarkoma.
English: Panretin is a medicine used to treat the skin lesions seen in AIDS patients with Kaposi's sarcoma (a type of skin cancer).
Slovenian: Zdravilo Panretin se uporablja za zdravljenje kožnih lezij, ki se pojavijo pri bolnikih z aidsom, ki imajo Kaposijev sarkom (vrsto kožnega raka).
English: A patient was considered to have responded to treatment if their lesions reduced in area or flattened by a certain amount depending on the type of lesions.
Slovenian: Če so se pri bolniku lezije po površini zmanjšale ali sploščile za določeno količino glede na vrsto lezije, se je štelo, da se je bolnik odzval na zdravljenje.
English: For the full list of all side effects reported with Panretin, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Panretin, glejte navodilo za uporabo.
English: How does Panretin work?
Slovenian: Kako zdravilo Panretin deluje?
English: Panretin was more effective than placebo at treating Kaposi's sarcoma.
Slovenian: Zdravilo Panretin je bilo pri zdravljenju Kaposijevega sindroma učinkovitejše od placeba.
English: Healthy skin around the lesion should be avoided.
Slovenian: Bolniki gela ne smejo nanašati na zdravo kožo okrog lezij.
English: How is Panretin used?
Slovenian: Kako se zdravilo Panretin uporablja?
English: Depending on each lesion's response to treatment, the number of applications can be increased to three or four times a day.
Slovenian: Število nanosov gela se lahko poveča na od tri- do štirikrat dnevno, odvisno od odziva posamezne lezije na zdravljenje.
English: Before opening: 2 years.
Slovenian: Pred odprtjem: 2 leti